OpenAI has engaged with the U.S. Food and Drug Administration (FDA) to explore ways artificial intelligence can enhance the efficiency of drug evaluations. The discussions include a project named cderGPT, targeting improvements within the FDA's Center for Drug Evaluation, which oversees drug regulation. The aim is to reduce the extensive timeline typically seen in drug development processes, which can exceed a decade. Despite the potential benefits of AI, concerns about the reliability of AI models remain significant.
OpenAI has met with officials from the U.S. Food and Drug Administration to discuss the agency's use of AI to speed up drug evaluations, Wired reported on Wednesday.
AI has long been touted as a potential accelerant that could be used throughout drug development, making some notoriously slow steps more efficient.
Collection
[
|
...
]